BLA 208157 · Baxter Hlthcare Corp
Myxredlin
Insulin Human · Intravenous · Insulin
Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jun 20, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3,803
844 Phase 3, 184 recruiting
FAERS reports
6,745
5,542 serious, 779 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 7, 2025.
MYXREDLIN is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).
Mechanism: The primary activity of insulin, including MYXREDLIN is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MYXREDLIN · INSULIN HUMAN 100 UNITS/100ML (1 UNIT/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Human" as an intervention, any sponsor and status, largest first.
- Study of Vitamin D and Omega-3 Supplementation for Preventing DiabetesPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT01633177 · 22,220 participants · Start Nov 2011 · Primary completion May 30, 2024
Drug: Omega-3 fatty acid (fish oil); Fish oil placebo · For: Type 2 Diabetes
Sites: Boston, Massachusetts
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Tight Versus Liberal Blood Glucose Control in Adult Critically Ill PatientsPivotal-lookingActive, not recruiting
KU LeuvenAcademic, hospital or other
NCT03665207 · 9,230 participants · Start Sep 18, 2018 · Primary completion Nov 30, 2022
Drug: Insulin · For: Critical Illness; Hyperglycemia
Sites: Ghent, Belgium; Hasselt, Belgium; Leuven, Belgium · 4 sites in all
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01986881 · 8,246 participants · Start Nov 4, 2013 · Primary completion Dec 27, 2019
Drug: Ertugliflozin; Placebo and 1 more · For: Type 2 Diabetes Mellitus
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular EventsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01959529 · 7,637 participants · Start Oct 29, 2013 · Primary completion Oct 16, 2016
Drug: insulin degludec; insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Montgomery, Alabama; Gilbert, Arizona · 446 sites in all
- A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00399724 · 7,376 participants · Start Mar 2002 · Primary completion Aug 2003
Drug: Insulin glargine · For: Diabetes Mellitus, Type 2
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased966
- hypoglycaemia434
- drug ineffective380
- dyspnoea331
- hyperglycaemia329
- diarrhoea325
- blood glucose decreased295
- off label use291
- headache257
- nausea250
- fall246
- weight decreased242
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 54 |
| 2005 | 54 |
| 2006 | 44 |
| 2007 | 73 |
| 2008 | 69 |
| 2009 | 67 |
| 2010 | 76 |
| 2011 | 100 |
| 2012 | 96 |
| 2013 | 160 |
| 2014 | 369 |
| 2015 | 909 |
| 2016 | 196 |
| 2017 | 143 |
| 2018 | 385 |
| 2019 | 349 |
| 2020 | 310 |
| 2021 | 410 |
| 2022 | 665 |
| 2023 | 607 |
| 2024 | 651 |
| 2025 | 585 |
| 2026 | 373 |
Recalls
1 FDA enforcement reports for this application.
Aug 6, 2026 · Class II · Ongoing
CGMP Deviations
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Hypoglycaemia induced by exogenous insulin--'human' and animal insulin compared.
Airey CM, Williams DR, Martin PG, et al. · Diabet Med 2000 · Comparative Study, Research Support, Non-U.S. Gov't
- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K, Jeitler K, Berghold A, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis.
Czech M, Rdzanek E, Pawwska J, et al. · BMC Endocr Disord 2015 · Meta-Analysis, Systematic Review
- (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T, Engler J, Siebenhofer A, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Different insulin types and regimens for pregnant women with pre-existing diabetes.
O'Neill SM, Kenny LC, Khashan AS, et al. · Cochrane Database Syst Rev 2017 · Research Support, Non-U.S. Gov't, Systematic Review
- Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus.
McGill JB, Weiss D, Grant M, et al. · J Diabetes 2021 · Randomized Controlled Trial, Equivalence Trial
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.